| Biliary Disease |
1 |
1 |
| Renal Failure |
0 |
0.83 |
| Non-Alcoholic Fatty Liver Disease |
0 |
0.69 |
| Liver Disease |
0 |
0.68 |
| Transjugular Intrahepatic Portosystemic Shunt |
0 |
0.63 |
| Hepatocellular Carcinoma |
0 |
0.6 |
| Liver |
0 |
0.6 |
| Liver Transplantation |
0 |
0.51 |
| Cirrhosis |
0 |
0.42 |
| Acute Kidney Injury |
0 |
0.34 |
| Obesity |
0 |
0.34 |
| Chronic Kidney Disease |
0 |
0.32 |
| Bariatric Surgery |
0 |
0.29 |
| Hepatic Encephalopathy |
0 |
0.25 |
| Surgery |
0 |
0.24 |
| Hypertension |
0 |
0.23 |
| Encephalopathy |
0 |
0.18 |
| Kidney |
0 |
0.18 |
| Transplantation |
0 |
0.18 |
| Renal Disease |
0 |
0.17 |
| Transjugular Intrahepatic Portosystemic Shunt Procedure |
0 |
0.17 |
| Beta-Adrenergic Agonist |
0 |
0.12 |
| Clinical Research |
0 |
0.12 |
| Healthcare and Medical Technology |
0 |
0.12 |
| Hepatorenal Syndrome |
0 |
0.12 |
| Injury |
0 |
0.12 |
| Nonalcoholic Steatohepatitis |
0 |
0.12 |
| Type 2 Diabetes Mellitus |
0 |
0.12 |
| Wound Management |
0 |
0.12 |
| GLP-1 Receptor Agonist |
0 |
0.1 |
| Ablation |
0 |
0.06 |
| Adjuvant Setting |
0 |
0.06 |
| Biomarker |
0 |
0.06 |
| Blood |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Child |
0 |
0.06 |
| Endoscopy |
0 |
0.06 |
| Esophagus |
0 |
0.06 |
| Fellowship |
0 |
0.06 |
| Grant |
0 |
0.06 |
| Impairment |
0 |
0.06 |
| Internship |
0 |
0.06 |
| Metabolism |
0 |
0.06 |
| Pennsylvania |
0 |
0.06 |
| Portal Hypertension |
0 |
0.06 |
| Receptors |
0 |
0.06 |
| Resection |
0 |
0.06 |
| Texas |
0 |
0.06 |
| Ultrasonography |
0 |
0.06 |
| Varices |
0 |
0.06 |